RAPT THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.1 USD | +3.85% |
|
+1.89% | -67.40% |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 282M 22.57B |
|---|---|---|---|---|---|
| Net income 2024 * | -129M -10.33B | Net income 2025 * | -164M -13.13B | EV / Sales 2024 * | - |
| Net cash position 2024 * | 132M 10.58B | Net cash position 2025 * | 181M 14.51B | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-2.6
x | P/E ratio 2025 * |
-2.61
x | Employees | 131 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92% |
More Fundamentals
* Assessed data
More news
Latest transcript on RAPT Therapeutics, Inc.
More recommendations
More press releases
| 1 day | +3.85% | ||
| 1 week | +1.89% | ||
| Current month | -9.80% | ||
| 1 month | -3.57% | ||
| 3 months | -67.97% | ||
| 6 months | -30.89% | ||
| Current year | -67.40% |
1 week
7.52
8.31
1 month
7.529.65
Current year
6.8627.35
1 year
6.8627.35
3 years
6.8643.26
5 years
6.8651.21
10 years
6.8651.21
| Managers | Title | Age | Since |
|---|---|---|---|
Brian Wong
CEO | Chief Executive Officer | 52 | 31/07/15 |
Rodney Young
DFI | Director of Finance/CFO | 61 | 01/12/19 |
Jim Farmer
CTO | Chief Tech/Sci/R&D Officer | - | 03/05/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mary Gray
BRD | Director/Board Member | 71 | 03/12/19 |
William Rieflin
CHM | Chairman | 64 | 30/04/15 |
Wendye Robbins
BRD | Director/Board Member | 63 | 21/10/19 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.05% | 0 M€ | 0.00% | - | |
| 0.05% | 0 M€ | 0.00% | - | |
| 0.02% | 237 M€ | +2.89% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 8.1 | +3.85% | 466,173 |
| 25/04/24 | 7.8 | -1.27% | 855,152 |
| 24/04/24 | 7.9 | -1.25% | 291,848 |
| 23/04/24 | 8 | +1.78% | 333,837 |
| 22/04/24 | 7.86 | -1.13% | 377,331 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its drug discovery and development engine, it develops selective small molecules designed to modulate the critical immune responses underlying these diseases. Its lead inflammation drug candidate, zelnecirnon (RPT193), and its lead oncology drug candidate, tivumecirnon (FLX475), each target C-C motif chemokine receptor 4 (CCR4), a drug target that potentially has broad applicability in inflammatory diseases and oncology. Its inflammation drug candidate, zelnecirnon, is designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its oncology drug candidate, tivumecirnon, is designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors.
Calendar
07/05/2024
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
8.1
USD
Average target price
22
USD
Spread / Average Target
+171.60%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -67.40% | 282M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- RAPT Stock
